ADIAL PHARMACEUTICALS

Company snapshot

Our Mission: Innovative Therapies to Change Patients' Lives At our core, we are driven by a clear mission: to deliver innovative, high-quality therapies that make a meaningful difference in patients’ lives. With a focus on specialty and niche medicines, Alida is committed to addressing unmet medical needs across multiple therapeutic areas, including rare diseases, cardiology, CNS, oncology, and su

• 1 approved product(s) across US/EU regulatory metadata.
• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for ADIAL PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ADIAL PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   Trametinib (GSK1120212) — Phase 2

2. Jun 8, 2026 Clinical update

   Nizatidine — Phase 1

3. Jun 8, 2026 Clinical update

   Axitinib — Phase 2

4. Jun 8, 2026 Clinical update

   AD04 (ondansetron) — Phase 3

5. May 23, 2026 Clinical update

   Erythromycin lactobionate — Phase 1

View all clinical trial activity →

• What is ADIAL PHARMACEUTICALS?

  Alida Pharmaceuticals is a pharma organization headquartered in CHARLOTTESVILLE, VA, ES. It trades on NYSE under ticker ADIL. Primary therapeutic focus areas include Melanoma, Alcohol Use Disorder, Tooth Loss, Diabetes Mellitus, Type 1, Gastroparesis. NovaPharmaNews links 6 clini

• Is ADIAL PHARMACEUTICALS publicly traded?

  Yes. ADIAL PHARMACEUTICALS is listed with ticker ADIL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ADIAL PHARMACEUTICALS develop or market?

  We link 9 drug profile(s) where ADIAL PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/adial-pharmaceuticals-inc#company-drugs.

• What are the latest developments for ADIAL PHARMACEUTICALS?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ADIAL PHARMACEUTICALS focus on?

  ADIAL PHARMACEUTICALS focuses on Melanoma, Alcohol Use Disorder, Tooth Loss based on our analysis of their pipeline programs and drug development activities.